AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21055649 — intervention group
Group type: EXPERIMENTAL
Intervention: HFMS
Number of subjects: 315
Study 21055649 — intervention group
Group type: COMPARATOR
Intervention: SC
Number of subjects: 315
Study 18043058 — intervention group
Group type: EXPERIMENTAL
Intervention: P6 acupuncture group (n = 110)
Number of subjects: 220
Study 18043058 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 110)
Number of subjects: 220
Study 16102903 — intervention group
Group type: EXPERIMENTAL
Intervention: LRRK 2 G 2019 S mutation screening in Parkinson's disease patients
Number of subjects: 0
Study 16102903 — intervention group
Group type: COMPARATOR
Intervention: LRRK 2 G 2019 S mutation screening in other neurodegenerative diseases (Alzheimer's, Progressive Supranuclear Palsy, Multiple System Atrophy, frontotemporal dementia)
Number of subjects: 0
Study 16102903 — intervention group
Group type: COMPARATOR
Intervention: Neurologically normal controls
Number of subjects: 0
Study 12239432 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene plasma levels in skin type I
Number of subjects: 174
Study 12239432 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene plasma levels in skin type II
Number of subjects: 174
Study 12239432 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene plasma levels in skin type III
Number of subjects: 174
Study 12239432 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene plasma levels in skin type IV
Number of subjects: 174
Study 12239432 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene content in oral mucosa epithelium (OMC) in skin type I
Number of subjects: 174
Study 12239432 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene content in oral mucosa epithelium (OMC) in skin type IV
Number of subjects: 174
Study 12239432 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene content in OMC in skin type I
Number of subjects: 174
Study 12239432 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene content in OMC in skin type IV
Number of subjects: 174
Study 12239432 — intervention group
Group type: COMPARATOR
Intervention: Comparison of beta-carotene levels in smokers vs non-smokers
Number of subjects: 174
Study 12239432 — intervention group
Group type: COMPARATOR
Intervention: Comparison of beta-carotene levels in non-melanoma and melanoma skin cancer patients
Number of subjects: 174
Study 10221882 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole
Number of subjects: 85
Study 10221882 — intervention group
Group type: COMPARATOR
Intervention: Nystatin
Number of subjects: 85
Study 7593706 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 139
Study 7593706 — intervention group
Group type: COMPARATOR
Intervention: haloperidol
Number of subjects: 139
Study 7593706 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 139
Study 2390431 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS 205-930 (20 mg)
Number of subjects: 12
Study 2390431 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS 205-930 (10 mg)
Number of subjects: 12
Study 2390431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6291763 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM combination chemotherapy (cyclophosphamide, doxorubicin, and methotrexate)
Number of subjects: 104
Study 6291763 — intervention group
Group type: COMPARATOR
Intervention: Single‐agent sequential chemotherapy (cyclophosphamide, doxorubicin, and methotrexate)
Number of subjects: 104
Study 6291763 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM combination chemotherapy
Number of subjects: 104
Study 6291763 — intervention group
Group type: COMPARATOR
Intervention: Single‐agent sequential chemotherapy
Number of subjects: 104
Study 6291763 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for CAM
Number of subjects: 104
Study 6291763 — intervention group
Group type: COMPARATOR
Intervention: Overall survival for single-agent sequential chemotherapy
Number of subjects: 104
Study 31204078 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab monotherapy
Number of subjects: 27
Study 28816924 — intervention group
Group type: EXPERIMENTAL
Intervention: DRSP/EE (drospirenone and ethinyl estradiol)
Number of subjects: 32
Study 28816924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 26799573 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance therapy (MRT) - 10 sessions of one hour daily
Number of subjects: 97
Study 26799573 — intervention group
Group type: COMPARATOR
Intervention: Placebo MRT
Number of subjects: 97
Study 26799573 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance therapy (MRT)
Number of subjects: 97
Study 25347024 — intervention group
Group type: EXPERIMENTAL
Intervention: PBS skills training intervention
Number of subjects: 226
Study 25347024 — intervention group
Group type: COMPARATOR
Intervention: Study skills control condition
Number of subjects: 226
Study 23093256 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg progesterone vaginal gel
Number of subjects: 84
Study 23093256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 19789415 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterax (2 mg perindopril/0.625 mg indapamide)
Number of subjects: 30
Study 19789415 — intervention group
Group type: COMPARATOR
Intervention: Cilazapril (2.5 mg)
Number of subjects: 30
Study 17257820 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPSV (noninvasive pressure support ventilation) administered pre‐ and postoperatively for 7 days at home before surgery and 3 days postoperatively
Number of subjects: 32
Study 17257820 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPSV
Number of subjects: 32
Study 17257820 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NIPSV)
Number of subjects: 32
Study 14982787 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dalbavancin (single doses starting at 140 mg, escalating to 1120 mg; multiple doses with a 300 mg loading dose followed by six daily 30 mg maintenance doses)
Number of subjects: 52
Study 14982787 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dalbavancin (various doses)
Number of subjects: 52
Study 11744606 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 0
Study 11744606 — intervention group
Group type: COMPARATOR
Intervention: Probenecid
Number of subjects: 0
Study 11744606 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 0
Study 11744606 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 0
Study 9864778 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term corticosteroid therapy (up to 21 days)
Number of subjects: 0
Study 7990700 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric high-protein diet (HP diet, 10 subjects)
Number of subjects: 25
Study 7990700 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric high-carbohydrate diet (HC diet, 15 subjects)
Number of subjects: 25
Study 2646350 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline, 60 mg daily
Number of subjects: 315
Study 2646350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 31012562 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical test product (peptide combination)
Number of subjects: 11
Study 31012562 — intervention group
Group type: COMPARATOR
Intervention: Bland emollient (control)
Number of subjects: 11
Study 28679486 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure time exercise of moderate intensity (MOD, ∼50% VO2peak)
Number of subjects: 130
Study 28679486 — intervention group
Group type: EXPERIMENTAL
Intervention: Active commuting (BIKE)
Number of subjects: 130
Study 28679486 — intervention group
Group type: COMPARATOR
Intervention: Habitual lifestyle (Control, CON)
Number of subjects: 130
Study 28679486 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure time exercise of vigorous intensity (VIG, ∼70% VO2peak)
Number of subjects: 130
Study 28679486 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen, von Willebrand factor (vWF), tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor type 1 (PAI-1)
Number of subjects: 130
Study 25727857 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolastin-C (60 mg/kg) administered weekly over 3 years
Number of subjects: 0
Study 25727857 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolastin-C (120 mg/kg) administered weekly over 3 years
Number of subjects: 0
Study 25727857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25727857 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolastin-C (60 mg/kg) and Prolastin-C (120 mg/kg)
Number of subjects: 0
Study 23898805 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Treatment (IT) (N=30)
Number of subjects: 50
Study 23898805 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU) (N=20)
Number of subjects: 50
Study 22141750 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP care
Number of subjects: 0
Study 22141750 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 0
Study 19484786 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg intravenously on Day 1)
Number of subjects: 40
Study 19484786 — intervention group
Group type: COMPARATOR
Intervention: Control (no infusion during ADT)
Number of subjects: 40
Study 16967399 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent nasogastric feeding
Number of subjects: 107
Study 16967399 — intervention group
Group type: COMPARATOR
Intervention: Continuous feeding
Number of subjects: 107
Study 16967399 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of dopamine
Number of subjects: 107
Study 15208226 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Number of subjects: 600
Study 15208226 — intervention group
Group type: COMPARATOR
Intervention: On-site specialist consultation
Number of subjects: 600
Study 15208226 — intervention group
Group type: COMPARATOR
Intervention: On-site general practitioner consultation
Number of subjects: 600
Study 15208226 — intervention group
Group type: EXPERIMENTAL
Intervention: All consultation modalities
Number of subjects: 600
Study 15208226 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 600
Study 15126176 — intervention group
Group type: EXPERIMENTAL
Intervention: Submacular surgery
Number of subjects: 120
Study 15126176 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 120
Study 10410299 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 459
Study 10410299 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits and vegetables diet
Number of subjects: 459
Study 10410299 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 459
Study 8712061 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD + SUD group
Number of subjects: 28
Study 8712061 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-dependent group
Number of subjects: 28
Study 2193424 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-free haemodialysate (Actovegin)
Number of subjects: 103
Study 2193424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 631013 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone test dose pupillography
Number of subjects: 107
Study 631013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 31533751 — intervention group
Group type: EXPERIMENTAL
Intervention: wIRA treatment
Number of subjects: 120
Study 31533751 — intervention group
Group type: COMPARATOR
Intervention: no-wIRA treatment (control group)
Number of subjects: 120
Study 28078599 — intervention group
Group type: EXPERIMENTAL
Intervention: Besifloxacin ophthalmic suspension 0.6%
Number of subjects: 33
Study 28078599 — intervention group
Group type: COMPARATOR
Intervention: Gatifloxacin ophthalmic solution 0.3%
Number of subjects: 33
Study 26270287 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) home visits
Number of subjects: 373
Study 26270287 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 373
Study 25043278 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sIPV
Number of subjects: 20
Study 25043278 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose adjuvanted sIPV
Number of subjects: 20
Study 25043278 — intervention group
Group type: COMPARATOR
Intervention: Conventional IPV (wIPV)
Number of subjects: 20
Study 25043278 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 20
Study 23159252 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid plus personalized risk assessment
Number of subjects: 825
Study 23159252 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid alone
Number of subjects: 825
Study 23159252 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 825
Study 19753300 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized rIFN‐gamma1b
Number of subjects: 89
Study 19753300 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN‐gamma1b (both nebulized and subcutaneous)
Number of subjects: 89
Study 19753300 — intervention group
Group type: COMPARATOR
Intervention: DOTS
Number of subjects: 89
Study 19753300 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous rIFN‐gamma1b
Number of subjects: 89
Study 17319412 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct laryngoscopy (group-I)
Number of subjects: 100
Study 17319412 — intervention group
Group type: COMPARATOR
Intervention: Intubating Laryngeal Mask Airway (group-II)
Number of subjects: 100
Study 17319412 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 15240088 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual support group (12 sessions over 3 months)
Number of subjects: 48
Study 15240088 — intervention group
Group type: COMPARATOR
Intervention: Usual outpatient care only
Number of subjects: 48
Study 11163560 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmeda Bioactive Surface
Number of subjects: 300
Study 11163560 — intervention group
Group type: EXPERIMENTAL
Intervention: Baxter Duraflo II
Number of subjects: 300
Study 11163560 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 11163560 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin coating (general)
Number of subjects: 300
Study 9680884 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite or laminate (sandwich) composite sealant restorations
Number of subjects: 278
Study 8006914 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of quinapril and hydrochlorothiazide (HCTZ)
Number of subjects: 460
Study 8006914 — intervention group
Group type: COMPARATOR
Intervention: Quinapril monotherapy
Number of subjects: 460
Study 8006914 — intervention group
Group type: COMPARATOR
Intervention: HCTZ monotherapy
Number of subjects: 460
Study 8006914 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril and HCTZ combination therapy
Number of subjects: 460
Study 8006914 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (40 mg) with HCTZ
Number of subjects: 460
Study 2630288 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-gamma 2 amalgam fillings (30 subjects)
Number of subjects: 45
Study 2630288 — intervention group
Group type: COMPARATOR
Intervention: New fillings (15 subjects)
Number of subjects: 45
Study 31427788 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence and game elements decision support approach
Number of subjects: 0
Study 31427788 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28684643 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG plus clarithromycin
Number of subjects: 81
Study 28684643 — intervention group
Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 81
Study 26488734 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver dressings (SD)
Number of subjects: 55
Study 26488734 — intervention group
Group type: COMPARATOR
Intervention: Regular dressings (RD)
Number of subjects: 55
Study 23978167 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative social preference scores based on teacher ratings
Number of subjects: 188
Study 21484950 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 0
Study 19516176 — intervention group
Group type: COMPARATOR
Intervention: 100 mg tea flavonoids/day
Number of subjects: 19
Study 19516176 — intervention group
Group type: COMPARATOR
Intervention: 200 mg tea flavonoids/day
Number of subjects: 19
Study 19516176 — intervention group
Group type: COMPARATOR
Intervention: 400 mg tea flavonoids/day
Number of subjects: 19
Study 19516176 — intervention group
Group type: COMPARATOR
Intervention: 800 mg tea flavonoids/day
Number of subjects: 19
Study 19516176 — intervention group
Group type: COMPARATOR
Intervention: black tea intake
Number of subjects: 19
Study 17369570 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aids
Number of subjects: 0
Study 15300275 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention carried out in Mushin LGA for four weeks.
Number of subjects: 0
Study 15300275 — intervention group
Group type: COMPARATOR
Intervention: Control LGA (Ikeja) with no intervention.
Number of subjects: 0
Study 11479470 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting with >=1 heparin-coated stent
Number of subjects: 410
Study 11479470 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 410
Study 11479470 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of occlusion <= 6 weeks
Number of subjects: 410
Study 11479470 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of occlusion > 6 weeks
Number of subjects: 410
Study 9756247 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy density (LED) diet (357 kJ/100 g)
Number of subjects: 6
Study 9756247 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy density (HED) diet (629 kJ/100 g)
Number of subjects: 6
Study 7923965 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril pretreatment in normal subjects (group II)
Number of subjects: 26
Study 7923965 — intervention group
Group type: COMPARATOR
Intervention: Arginine infusion without captopril (group I)
Number of subjects: 26
Study 7923965 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine infusion in IgA nephropathy patients (group III)
Number of subjects: 26
Study 7923965 — intervention group
Group type: COMPARATOR
Intervention: Arginine infusion in normals without captopril (group I)
Number of subjects: 26
Study 3207855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergoloid mesylates (3-9 mg) administered via oral swallow and sublingual tablets, solution, under fasted and with meal conditions.
Number of subjects: 0
Study 31954563 — intervention group
Group type: EXPERIMENTAL
Intervention: High milk replacer (HI) at 1.498 kg of MR/d
Number of subjects: 48
Study 31954563 — intervention group
Group type: COMPARATOR
Intervention: Low milk replacer (LO) at 0.749 kg of MR/d
Number of subjects: 48
Study 31628121 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli sprout extract (24 mg of activated sulforaphane, twice daily until delivery)
Number of subjects: 180
Study 31628121 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to broccoli sprout extract)
Number of subjects: 180
Study 27935788 — intervention group
Group type: EXPERIMENTAL
Intervention: Endowment condition
Number of subjects: 102
Study 27935788 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoughts structuring instructions
Number of subjects: 102
Study 25973838 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping alone (group A)
Number of subjects: 148
Study 25973838 — intervention group
Group type: COMPARATOR
Intervention: Clipping plus epinephrine-saline injection (group B)
Number of subjects: 148
Study 23086020 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (1 mg)
Number of subjects: 15
Study 23086020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 22094838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified juice drink
Number of subjects: 100
Study 22094838 — intervention group
Group type: COMPARATOR
Intervention: Non-fortified juice
Number of subjects: 100
Study 22094838 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 17603709 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott Propofol
Number of subjects: 90
Study 17603709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pofol
Number of subjects: 90
Study 17603709 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1% Fresenius
Number of subjects: 90
Study 15752879 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term androgen deprivation
Number of subjects: 1003
Study 15752879 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 1003
Study 11930309 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV immunoglobulin therapy
Number of subjects: 77
Study 11930309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 9455954 — intervention group
Group type: EXPERIMENTAL
Intervention: SPNT test in WAD group with dizziness
Number of subjects: 75
Study 9455954 — intervention group
Group type: EXPERIMENTAL
Intervention: SPNT test in WAD group without dizziness
Number of subjects: 75
Study 9455954 — intervention group
Group type: COMPARATOR
Intervention: SPNT test in control patients with central and peripheral vertigo and healthy subjects
Number of subjects: 75
Study 8564323 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) as an adjuvant to treatment as usual
Number of subjects: 31
Study 8564323 — intervention group
Group type: COMPARATOR
Intervention: Low-dose lithium therapy
Number of subjects: 31
Study 8564323 — intervention group
Group type: COMPARATOR
Intervention: Placebo maintenance therapy
Number of subjects: 31
Study 2374273 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 kcal/d diet for 48 weeks
Number of subjects: 18
Study 2374273 — intervention group
Group type: COMPARATOR
Intervention: 420 kcal/d diet for 16 weeks followed by a conventional reducing diet for the remainder of treatment
Number of subjects: 18
Study 949108 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate infusion (2.55 mg/kg)
Number of subjects: 15
Study 949108 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-N2O-O2 anaesthesia with etomidate
Number of subjects: 15